Related references
Note: Only part of the references are listed.Initiation and adherence to adjuvant endocrine therapy among urban, insured American Indian/Alaska Native breast cancer survivors
Marc A. Emerson et al.
CANCER (2021)
The impact of the introduction of generic aromatase inhibitors on adherence to hormonal therapy over the full course of 5-year treatment for breast cancer
Siyu Ma et al.
CANCER (2020)
Chemotherapy Associated Ovarian Failure
Davide Mauri et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
Influence of adherence to adjuvant endocrine therapy on disease-free and overall survival: a population-based study in Catalonia, Spain
Rebeca Font et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database
Thomas Helland et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Prevalence of and factors associated with primary medication non-adherence in chronic disease: A systematic review and meta-analysis
McVin Hua Heng Cheen et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2019)
Nonadherence to Tamoxifen in Breast Cancer Survivors: A 12 Month Longitudinal Analysis
Zoe Moon et al.
HEALTH PSYCHOLOGY (2019)
Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial
J. M. S. Bartlett et al.
ANNALS OF ONCOLOGY (2019)
Primary non-adherence to adjuvant endocrine therapy in older women with breast cancer.
Vanina Tchuente et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity
W. Wulaningsih et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
A Systematic Review of Medication Adherence Thresholds Dependent of Clinical Outcomes
Pascal C. Baumgartner et al.
FRONTIERS IN PHARMACOLOGY (2018)
Economic impact of medication non-adherence by disease groups: a systematic review
Rachelle Louise Cutler et al.
BMJ OPEN (2018)
An upper and lower bound of the Medication Possession Ratio
Christian M. Sperber et al.
PATIENT PREFERENCE AND ADHERENCE (2017)
Tamoxifen from Failed Contraceptive Pill to Best-Selling Breast Cancer Medicine: A Case-Study in Pharmaceutical Innovation
Viviane M. Quirke
FRONTIERS IN PHARMACOLOGY (2017)
Polypharmacy and Adherence to Adjuvant Endocrine Therapy for Breast Cancer
Gregory S. Calip et al.
JOURNAL OF ONCOLOGY PRACTICE (2017)
aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer.
Richard G. Gray et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Medication Adherence: Truth and Consequences
Marie T. Brown et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2016)
Is it best to expect the worst? Influence of patients' side-effect expectations on endocrine treatment outcome in a 2-year prospective clinical cohort study
Y. Nestoriuc et al.
ANNALS OF ONCOLOGY (2016)
Two Years of Adjuvant Tamoxifen Provides a Survival Benefit Compared With No Systemic Treatment in Premenopausal Patients With Primary Breast Cancer: Long-Term Follow-Up (> 25 years) of the Phase III SBII:2pre Trial
Maria Ekholm et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence
Jacquie H. Chirgwin et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Barriers and facilitators to endocrine therapy adherence among underserved hormone-receptor-positive breast cancer survivors: a qualitative study
Kristen J. Wells et al.
SUPPORTIVE CARE IN CANCER (2016)
Medication Adherence Measures: An Overview
Wai Yin Lam et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Factors influencing adherence to cancer treatment in older adults with cancer: a systematic review
M. T. E. Puts et al.
ANNALS OF ONCOLOGY (2014)
A nested case-control study of adjuvant hormonal therapy persistence and compliance, and early breast cancer recurrence in women with stage I-III breast cancer
T. I. Barron et al.
BRITISH JOURNAL OF CANCER (2013)
The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study
C. McCowan et al.
BRITISH JOURNAL OF CANCER (2013)
Medication (Re)fill Adherence Measures Derived from Pharmacy Claims Data in Older Americans: A Review of the Literature
Elisabeth Lilian Pia Sattler et al.
DRUGS & AGING (2013)
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
Christina Davies et al.
LANCET (2013)
Compliance and persistence of endocrine adjuvant breast cancer therapy
Uwe Gueth et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Clinical and biomarker predictors of side effects from tamoxifen
Wendy Lorizio et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study
Annette Wigertz et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review
Caitlin C. Murphy et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer
Rebecca L. Sedjo et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer
Dawn L. Hershman et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Good and poor adherence: optimal cut-point for adherence measures using administrative claims data
Sudeep Karve et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer
U. Gueth et al.
BRITISH JOURNAL OF CANCER (2008)
Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer
C. McCowan et al.
BRITISH JOURNAL OF CANCER (2008)
Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer
Cynthia Owusu et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer
Ann H. Partridge et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Medication compliance and persistence: Terminology and definitions
Joyce A. Cramer et al.
VALUE IN HEALTH (2008)
Early discontinuation of tamoxifen - A lesson for oncologists
Thomas I. Barron et al.
CANCER (2007)
Letrozole in the extended adjuvant setting: MA.17
Paul E. Goss
BREAST CANCER RESEARCH AND TREATMENT (2007)
Intentional and non-intentional non-adherence to medication amongst breast cancer patients
Louise Atkins et al.
EUROPEAN JOURNAL OF CANCER (2006)
Methods for evaluation of medication adherence and persistence using automated databases
Susan E. Andrade et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2006)
Validity of a prescription claims database to estimate medication adherence in older persons
R Grymonpre et al.
MEDICAL CARE (2006)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Adherence beliefs among breast cancer patients taking tamoxifen
EA Grunfeld et al.
PATIENT EDUCATION AND COUNSELING (2005)
Drug therapy - Adherence to medication
L Osterberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Adjuvant tamoxifen: Predictors of use, side effects, and discontinuation in older women
S Demissie et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
